Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2013Blood

ALX-0081 prevented cerebral artery thrombosis, induced early reperfusion, and reduced brain infarct area without provoking intracerebral bleeding in guinea pigs.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does ALX-0081 improve reperfusion and reduce brain infarct size without inducing hemorrhage compared to rtPA and tirofiban in a guinea pig MCA thrombosis model?

Population

Guinea pigs in a middle cerebral artery (MCA) thrombosis model

Comparison

ALX-0081 administered before, immediately after… vs Recombinant tissue plasminogen activator and the…

Design

Preclinical

Key result

ALX-0081 prevented cerebral artery thrombosis, induced early reperfusion, and reduced brain infarct area without provoking intracerebral bleeding in guinea pigs.

Authors

SMStefania MomiMTMichela TantucciMRMaarten Van Roy

Discussion

Loading...

Member takes

Overview

Warrants no change in acute stroke care; hypothesis-generating for GPIb-VWF blockade and requires human trials.

Structured PICO

Does ALX-0081 improve reperfusion and reduce brain infarct size without inducing hemorrhage compared to rtPA and tirofiban in a guinea pig MCA thrombosis model?

P
Population
Guinea pigs subjected to a middle cerebral artery (MCA) thrombosis model.
I
Intervention
ALX-0081 (Nanobody against the A1 domain of von Willebrand factor) administered before, immediately after, or 15 or 60 minutes after total occlusion of the MCA
C
Comparator
Recombinant tissue plasminogen activator (rtPA) and the GPIIb/IIIa antagonist tirofiban
O
Outcome
Reperfusion, brain infarct size, and brain hemorrhagesurrogate

ALX-0081, a GPIb-VWF blocking Nanobody, effectively induces reperfusion and reduces infarct size without causing intracerebral bleeding in a preclinical stroke model.

Cite This Study

Momi et al. (2013) studied Middle cerebral artery (MCA) thrombosis. ALX-0081 vs. rtPA and tirofiban was evaluated on Reperfusion, brain damage, and hemorrhage. ALX-0081 prevented cerebral artery thrombosis, induced early reperfusion, and reduced brain infarct area without provoking intracerebral bleeding in guinea pigs.

synapsesocial.com/papers/6a99d8fe8c596ba2983fd067https://doi.org/10.1182/blood-2012-11-464545
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.1998 · 242 citations
  2. 2Von Willebrand factor A1 blockade prevents platelet-mediated sustained occlusion for the treatment of arterial thrombosis2026
  3. 3FK419, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, Ameliorates Brain Infarction Associated with Thrombotic Focal Cerebral Ischemia in Monkeys: Comparison with Tissue Plasminogen Activator2005 · 21 citations
  4. 4The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention2011 · 20 citations
  5. 5FK419, a Novel Nonpeptide GPIIb/IIIa Antagonist, Restores Microvascular Patency and Improves Outcome in the Guinea-Pig Middle Cerebral Artery Thrombotic Occlusion Model: Comparison with Tirofiban2005 · 14 citations